| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Director
1 company
Nissim Darvish last filed a Form 4 in June 2023, as Director at CMMB. Nissim Darvish's net worth is not public. Form 4 filings only show shares in the companies where this person was an insider, as of the last filing.
At the last filing, the largest reported position was 1,200 shares of CMMB. Net of sales, the CMMB filings show accumulation of 1,200 shares.
Nissim Darvish has 5 Form 4 filings on record from April 2021 to June 2023, all as Director at Chemomab Therapeutics (CMMB), 2021–2023.
The 16 reported transactions were 15 option or other derivative awards and 1 open-market purchase.
Counted by filing, the open-market trades come to 1 purchase worth about $5K and no sales.
The only open-market purchase was 1,200 shares of CMMB at an average $4.28 on March 11, 2022, about $5K. Twelve months later CMMB was down 65%.
Shares as reported in the last Form 4 for each company; the most recent is from June 2023. Values use today's prices. Any trades after the last filing were not reported, so current holdings may differ.
| Date | Ticker | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| Mar 11, 2022 | CMMB Chemomab Therapeutics Ltd. | Director | Buy | 1,200 | $4.28 | $5,136.00 | New | -7.9% | -64.8% |